Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00393861
Recruitment Status : Completed
First Posted : October 29, 2006
Results First Posted : January 29, 2015
Last Update Posted : March 24, 2016
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Indiana University

Brief Summary:
The purpose of this study is to evaluate the effectiveness of oxaliplatin and bevacizumab in patients with refractory or relapsed germ cell tumors.

Condition or disease Intervention/treatment Phase
Neoplasms, Germ Cell and Embryonal Drug: Bevacizumab and Oxaliplatin Phase 2

Detailed Description:
This study proposes to look at the established combination of oxaliplatin and bevacizumab as used in colorectal cancer in refractory germ cell tumor patients. Oxaliplatin is a drug of known activity. Although bevacizumab has no single agent data, it combines dramatically well with numerous chemotherapy drugs, such as oxaliplatin increasing response rates and improving survival. Furthermore, VEG-F appears to be an important target in germ cell tumors as it does in so many other types of solid tumors. We will be using the identical dosages of oxaliplatin + bevacizumab as has been utilized in previously treated colorectal cancer, without the addition of 5-FU + leucovorin. This dose and schedule has been proven to be safe and effective.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Oxaliplatin Plus Bevacizumab Salvage Chemotherapy in Patients With Germ Cell Tumors
Study Start Date : October 2006
Actual Primary Completion Date : October 2012
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: oxaliplatin & bevacizumab Drug: Bevacizumab and Oxaliplatin
Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes




Primary Outcome Measures :
  1. Twelve Month Disease-free Survival Rate [ Time Frame: 12 month post completion of treatment ]
    The percent of patients being disease-free at 12 months after treatment initiation will be estimated with a 90% exact binomial confidence interval for the percent of patients receiving drug.


Secondary Outcome Measures :
  1. Objective Response Rate (Complete and Partial Response) [ Time Frame: completion of study, up to 5 years ]
    The percent of patients having an objective response (complete or partial response) will be estimated with a 90% exact binomial confidence interval for the percent of patients receiving drug per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

  2. Duration of Remission (CR + PR) [ Time Frame: completion of study, up to 5 years ]
    Will be examined using Kaplan-Meier estimates. Time from earliest confirmed remission criteria until death or progression will be calculated. If a patient continued to be in remission at the end of the study, they will be censored at their last evaluation in the analysis.

  3. Overall Survival [ Time Frame: completion of study, up to 5 years ]
    Will be examined using Kaplan-Meier estimates. Time until death or last evaluation will be calculated. If a patient did not die, they will be censored in the analysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histological or serologic proof of metastatic germ cell neoplasm (gonadal or extragonadal primary). Patients with seminoma and non-seminoma are eligible, as are women with ovarian germ cell tumors.
  • Patient's disease must not be amenable to cure with either surgery or chemotherapy in the opinion of the investigator.
  • Patients must have failed initial cisplatin combination chemotherapy administered with curative intent such as BEP, EP, VIP, or similar regimens.
  • Patients should have failed and demonstrated progressive disease with high dose chemotherapy such as carboplatin and etoposide. (With the exception of late relapse or primary mediastinal non-seminomatous germ cell tumor.
  • Patients with late relapse or primary mediastinal non-seminomatous germ cell tumors must have failed at least 1 salvage chemotherapy regimen.
  • Patients must have had prior exposure to paclitaxel, gemcitabine, or the combination of paclitaxel + gemcitabine.
  • Patients must have adequate hematologic function (WBC > 4,000/mm3 and platelets > 100,000/mm3) obtained < 4 weeks prior to registration.
  • Patients must have adequate hepatocellular function (SGOT < 4 x normal and Bilirubin <2.0 mg/dl) obtained < 4 weeks from protocol registration.
  • Serum Creatinine must be < 2.0 mg/dl obtained < 4 weeks from protocol registration.
  • Patients must have an ECOG performance status of 0, 1, or 2.
  • Patients must be at least 28 days post major surgery, open biopsy, or significant traumatic injury at time of study registration.
  • Patients must be at least 7 days post any minor surgical procedure, excluding placement of a vascular access device at the time of study registration.
  • Patients must be at least 18 years old at time of consent.

Exclusion Criteria:

  • Patients who have an active, unresolved infection and/or are receiving concurrent treatment with parenteral antibiotics are ineligible. Patients are eligible after antibiotics have been discontinued for at least 7 days.
  • Patients may not have any significant bleeding.
  • Patients with INR > 1.5 are not eligible unless the patient is on anti-coagulants with a therapeutic INR between 1.5 and 3. Patients on coumadin are not eligible unless they are on low dose coumadin to keep a vascular access device patent.
  • Patients with a history of arterial thromboses, unstable angina, transient ischemic attach (TIA), cerebral vascular accident (CVA), or a myocardial infarction within the last 6 months are not eligible.
  • Patients must not have known CNS metastases. A Head CT or MRI will be performed only if clinically indicated.
  • Patients must not have received any radiotherapy or chemotherapy within 28 days prior to study registration, and have recovered from all toxicity from prior treatments.
  • Patients must not have any prior history of hypertensive crisis or hypertensive encephalopathy.
  • Patients must not have New York Heart Association (NYHA) Grade II or greater congestive heart failure.
  • Patients must not have history of significant vascular disease.
  • Patients must not have evidence of bleeding diathesis or coagulopathy.
  • Patients must not have inadequately controlled hypertension (defined as systolic blood pressure 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications).
  • Patients must not have history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study registration.
  • Patients must not have serious, non-healing would, ulcer or bone fracture.
  • Patients must not have proteinuria at screening as demonstrated by a urine protein: Creatinine (UPC) ratio of ≥ 1.0.
  • Patients must not have a known sensitivity to any component of bevacizumab.
  • Patients must not be pregnant or lactating.
  • Patients must not have grade 3 or 4 neuropathy.
  • Females of child bearing potential must not be pregnant. A negative pregnancy test is required within 7 days prior to beginning treatment.

NOTE THE FOLLOWING GUIDELINES FOR USE IN THIS PROTOCOL:

  • Progressive metastatic disease will be documented by the appearance of metastatic lesions on PA and lateral chest x-ray, C.T. scan, or other imaging studies, or the presence of a rising serum HCG or AFP.
  • If a rising serum marker is the only evidence of progressive disease, at least 2 consecutive determinations must be done exhibiting serologic progression and alternative causes for increased serum levels of these substances must not be present [cross reaction with LH (tested if necessary by testosterone suppression of LH), ingestion of marijuana, hepatitis, etc.].
  • Patients will be considered to have failed a prior regimen if they fail to obtain a complete response per RECIST as outlined in section 6.
  • Patients with clinical situation of growing teratoma (normal or declining markers and radiographic or clinical progression) should be considered for surgery.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00393861


Locations
Layout table for location information
United States, Indiana
Indiana Univeristy Cancer Center
Indianapolis, Indiana, United States, 46202
United States, Pennsylvania
University of Pennsylvania:Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Indiana University
Genentech, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Lawrence Einhorn, MD Indiana Univeristy School of Medicine
Layout table for additonal information
Responsible Party: Indiana University
ClinicalTrials.gov Identifier: NCT00393861    
Other Study ID Numbers: 0609-11; IUCRO-0166
IUCRO-0166 ( Other Identifier: Indiana Univesity Simon Cancer Center )
AVF4003s ( Other Identifier: Industry Drug Sponsor )
First Posted: October 29, 2006    Key Record Dates
Results First Posted: January 29, 2015
Last Update Posted: March 24, 2016
Last Verified: February 2016
Keywords provided by Indiana University:
Germ Cell Tumor
Germ Cell Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Bevacizumab
Oxaliplatin
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors